Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. [electronic resource]
Producer: 20200326Description: 1244-1253 p. digitalISSN:- 1096-8652
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Apoptosis -- drug effects
- Benzylamines
- Bone Marrow -- drug effects
- Bortezomib -- administration & dosage
- Combined Modality Therapy
- Cyclams
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Female
- Gastrointestinal Diseases -- chemically induced
- Hematologic Diseases -- chemically induced
- Hematopoietic Stem Cell Transplantation
- Heterocyclic Compounds -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Male
- Maximum Tolerated Dose
- Middle Aged
- Multiple Myeloma -- drug therapy
- Neoplasm Proteins -- antagonists & inhibitors
- Neoplastic Stem Cells -- cytology
- Receptors, CXCR4 -- antagonists & inhibitors
- Recurrence
- Salvage Therapy
- Tumor Microenvironment -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.